PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis. Combining AI with their patented Morphology Feature Array® (MFA), PreciseDx provides highly accurate, actionable intelligence and disease insights that support better decision-making throughout the cancer care continuum.
Objectives
- Increase awareness and visibility of PreciseDx
- Drive thought leadership through subject matter expert’s POV on key industry topics: AI in healthcare, pathology/oncology innovation, etc
- Communicate scientifically-proven superiority over the standard of care and deliver key product messages, highlighting accuracy, timeliness, and cost-effectiveness
- Promote PreciseBreast™ as the new standard in assessing cancer risk of recurrence
2023 Results
53
articles
including: Fierce Healthcare, Fierce Biotech, Fierce Pharma, The Pathologist, WSJ Venture Capital, Forbes, Precision Medicine Online, Healthcare IT News, BioWorld MedTech, Clinical Lab Products, 360Dx, BioSpace, and Lab Pulse, among others
media impressions
99M+
media interviews to
build relationships
11
byline articles highlighting
thought leadership
7
Social media impressions
31,223
grew LinkedIn account
from 418 followers to
1,231
Website & Collateral
Media Highlights
